Thursday 16 October, 2025
Introduction: Chronic pain (CP) is highly prevalent with 20.4%, and 7.4% of the adult US population suffering from chronic pain…
Read morePoster: Drug/Disease Modelling - CNS
Exposure–response modelling of aripiprazole and brexpiprazole in adults and adolescents with schizophrenia to support extrapolation of efficacy in adolescents
Thursday 16 October, 2025
Introduction: The FDA recently released a general advice letter to sponsors, permitting the effectiveness of second-generation antipsychotics for the treatment…
Read morePopulation Pharmacokinetic-Pharmacodynamic Modeling of Escitalopram in Patients with Obsessive-Compulsive Disorder Using Yale-Brown Obsessive Compulsive Scale
Thursday 16 October, 2025
Objectives: The aim of this study was to develop pharmacokinetic-pharmacodynamic (PKPD) model of escitalopram concentration and its therapeutic effect on…
Read moreMS TreatSim: A clinical trial simulator for Relapsing-remitting Multiple Sclerosis
Thursday 16 October, 2025
Introduction: In the last decades, Relapsing-remitting Multiple Sclerosis (RRMS) diagnostic methodology and treatment options have undergone great improvements [1–3], positively…
Read morePopulation Pharmacokinetic Modeling of Quetiapine Lipid Core Nanocapsules in a Neurodevelopmental Animal Model of Schizophrenia
Thursday 16 October, 2025
Introduction: High variability in chronic SCZ response to treatment may be partially related to blood-brain barrier (BBB) dysfunction caused by…
Read morePharmacodynamic modelling of pupil diameter after noxious stimulus in patients undergoing surgery
Thursday 16 October, 2025
Objectives: Movement is an extensively characterised response to noxious stimulus. However, its applicability to assess intraoperative pain has limitations due…
Read moreQuantitative systems pharmacology model of key intraneuronal pathways regulating toxic protein accumulation in Alzheimer’s disease
Thursday 16 October, 2025
Objectives: Alzheimer’s disease (AD) is a complex neurodegenerative disorder, its pathogenesis mechanism is still debated and there is no effective…
Read moreTime-dependent pharmacokinetics of hydromethylthionine mesylate (HMTM), a tau aggregation inhibitor, in healthy volunteers and patients with Alzheimer’s Disease
Thursday 16 October, 2025
Objectives: Hydromethylthionine mesylate (HMTM) is an orally administered tau aggregation inhibitor (TAI), that also disaggregates pathological tau oligomers and filaments….
Read morePopulation pharmacokinetic modeling of total active moiety exposure following doses of TV 46000, a long-acting subcutaneous risperidone injection
Thursday 16 October, 2025
Background: TV‑46000 is a long-acting subcutaneous (sc) risperidone injection in development for treatment of schizophrenia with flexible dosing either once monthly…
Read moreA joint ketamine and esketamine exposure-response model of MADRS score in major depressive disorder to enable informed trial design for candidate drugs with similar mode of action
Thursday 16 October, 2025
Objectives: Ketamine and esketamine have been shown to have positive effects on Montgomery-Åsberg Depression Rating Scale (MADRS), an endpoint commonly…
Read more